High-value, cross-border and demand-inelastic: pharmaceuticals attract both counterfeiting proceeds and procurement corruption, and the parallel-trade layer gives illicit flows a legitimate-looking channel.
The rating above is indicative — it reflects inherent risk as assessed in the published frameworks, not a verdict on any business. Entire industries serve these sectors as business as usual; the rating your firm actually applies comes from its own business-wide risk assessment, where the sector factor combines with your customer base, controls and risk appetite.
Falsified and diverted medicines generate substantial criminal proceeds that need laundering, and the sector's international supply chains — ingredient sourcing, parallel imports, tender-based public procurement — offer both the value and the documentary complexity that laundering schemes exploit. Procurement corruption adds a PEP dimension wherever state health systems buy at scale.
The EU Supranational Risk Assessment's counterfeit-goods findings cover the segment, and the trade-based typologies apply in full: mis-priced or mis-described pharmaceutical shipments are still trade — just harder to price-check than commodity goods.
Verify authorisations and distribution licences, check pricing against reference benchmarks, apply PEP scrutiny to public-procurement relationships, and treat unusual routing as a trade-based-laundering flag. Sector risk combines with geography, the customer’s profile and the product to set the overall rating — and every client still needs sanctions, PEP and adverse-media screening on the parties themselves.
